Comparative Pharmacology
Head-to-head clinical analysis: TAPAZOLE versus THYRO BLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAPAZOLE versus THYRO BLOCK.
TAPAZOLE vs THYRO-BLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4) and reducing iodine organification and coupling of iodotyrosines.
THYRO-BLOCK (potassium iodide) inhibits thyroid hormone synthesis and release by blocking the oxidation of iodide to iodine, thereby preventing the incorporation of iodine into thyroglobulin. It also reduces the vascularity of the thyroid gland.
15-40 mg per day orally in 3 divided doses; maintenance: 5-15 mg per day orally once daily.
Oral, 120 mg every 12 hours (total daily dose 240 mg) starting 24 hours before exposure to radioactive iodine and continuing for 5–10 days as directed.
None Documented
None Documented
3-6 hours; clinically, effects persist longer due to intrathyroidal accumulation.
Terminal elimination half-life is approximately 36 hours (range 24-48 hours) in euthyroid patients; prolonged in hyperthyroid patients due to increased thyroid hormone binding and reduced clearance.
Primarily renal, approximately 65% excreted in urine as metabolites and unchanged drug; <10% eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug (80-90% of absorbed dose) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent